Patent Assignment
Reel/Frame 069213/0526
Change of Name
Recorded: 2024-10-22
Pages: 8
Assignor
FORTY SEVEN, INC.
Executed: 2024-09-23
Assignee
FORTY SEVEN, LLC
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA, 94404
Covered Properties
(39)
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Application:
62/523,182 →
Anti-SIRP-Alpha Antibodies and Related Methods
Application:
62/537,207 →
Anti-CD47 Agent-Based Ovarian Cancer Therapy
Application:
62/573,835 →
Treatment of Ovarian Cancer with anti-CD47 and anti-PD-L1
Application:
62/574,073 →
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
Application:
62/629,340 →
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
Application:
62/678,468 →
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
Application:
62/743,060 →
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
Application:
62/743,875 →
Combination Therapies for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia
Application:
62/916,949 →
Anti-CD47 Based Treatment of Blood Cancer
Application:
62/928,988 →
Combination Therapies for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia
Application:
62/944,851 →
Antibody Formulation
Application:
63/005,755 →
Anti-CD47 Based Treatment of Blood Cancer
Application:
63/031,418 →
Combination Therapies for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia
Application:
63/031,438 →
Anti-SIRP-Alpha Antibodies and Related Methods
Humanized, Mouse or Chimeric Anti-CD47 Monoclonal Antibodies
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Anti-CD47 Agent-Based Ovarian Cancer Therapy
Treatment of Ovarian Cancer with Anti-CD47 and Anti-Pd-L1
Application:
16/756,790 →
Publication:
US 2021/0047416
Humanized, Mouse or Chimeric Anti-CD47 Monoclonal Antibodies
Combination Therapies for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia
Anti-CD47 Based Treatment of Blood Cancer
Application:
17/083,556 →
Publication:
US 2021/0147568
Anti-Sirp-Alpha Antibodies and Related Methods
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Humanized, Mouse or Chimeric Anti-CD47 Monoclonal Antibodies
Antibody Formulation
Application:
17/916,994 →
Publication:
US 2023/0081265
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Combination Therapies for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia
Application:
18/367,973 →
Publication:
US 2024/0124578
Anti-CD47 Agent-Based Ovarian Cancer Therapy
Application:
18/373,655 →
Publication:
US 2024/0150461
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
Application:
18/389,605 →
Publication:
US 2024/0218077
Anti-CD47 Agent-Based Ovarian Cancer Therapy
PCT:
PCT/US2018/056441 ↗
Treatment of Ovarian Cancer with Anti-CD47 and Anti-Pd-L1
PCT:
PCT/US2018/056442 ↗
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
PCT:
PCT/US2018/038798 ↗
Anti-Sirp-Alpha Antibodies and Related Methods
PCT:
PCT/US2018/043699 ↗
Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
PCT:
PCT/US2019/017466 ↗
Combination Therapies for Treating Myelodysplastic Syndromes and Acute Myeloid Leukemia
PCT:
PCT/US2020/056011 ↗
Anti-CD47 Based Treatment of Blood Cancer
PCT:
PCT/US2020/057886 ↗
Antibody Formulation
PCT:
PCT/US2021/024937 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 28, 2017
From: CHAO, MARK P.; LIU, JIE; VOLKMER, JENS-PETER
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; FORTY SEVEN, INC.
Reel/Frame 043728/0343 →
Assignment of Assignor's Interest
Sep 28, 2017
From: MAJETI, RAVINDRA; WEISSMAN, IRVING L.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 043728/0318 →
Assignment of Assignor's Interest
Oct 25, 2017
From: TAKIMOTO, CHRIS HIDEMI MIZUFUNE
To: FORTY SEVEN, INC.
Reel/Frame 043948/0531 →
Assignment of Assignor's Interest
Nov 21, 2017
From: TAKIMOTO, CHRIS HIDEMI MIZUFUNE; CHAO, MARK PING; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 044193/0969 →
Assignment of Assignor's Interest
Feb 16, 2018
From: CHAO, MARK PING; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 044953/0381 →
Assignment of Assignor's Interest
Jun 7, 2018
From: CHAO, MARK PING; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 046020/0821 →
Assignment of Assignor's Interest
Jun 21, 2018
From: LIU, JIE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 046168/0731 →
Assignment of Assignor's Interest
Aug 1, 2018
From: LIU, JIE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 046529/0621 →
Assignment of Assignor's Interest
Jan 15, 2019
From: CHAO, MARK PING; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 048013/0247 →
Assignment of Assignor's Interest
Jan 23, 2019
From: CHAO, MARK PING; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 048114/0334 →
Assignment of Assignor's Interest
Feb 11, 2020
From: CHAO, MARK PING; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 051784/0247 →
Assignment of Assignor's Interest
Feb 12, 2020
From: CHAO, MARK PING; MAUTE, ROY LOUIS; HUANG, JIE; MIZUFUNE, CHRIS HIDEMI
To: FORTY SEVEN, INC.
Reel/Frame 051805/0865 →
Assignment of Assignor's Interest
Mar 25, 2020
From: VOLKMER, JENS-PETER; CHAO, MARK PING
To: FORTY SEVEN, INC.
Reel/Frame 052228/0813 →
Assignment of Assignor's Interest
Jun 23, 2020
From: CHALONS-COTTAVOZ, MARIE; LAHMAR, MEHDI; SCHWAMBORN, KLAUS; BELTRAMINELLI, NICOLA
To: BLINK BIOMEDICAL SAS
Reel/Frame 053017/0413 →
Assignment of Assignor's Interest
Jun 23, 2020
From: BLINK BIOMEDICAL SAS
To: FORTY SEVEN, INC.
Reel/Frame 053017/0383 →
Assignment of Assignor's Interest
Aug 13, 2020
From: TAKIMOTO, CHRIS HIDEMI MIZUFUNE; CHAO, MARK PING; VOLKMER, JENS-PETER
To: FORTY SEVEN, INC.
Reel/Frame 053488/0015 →
Assignment of Assignor's Interest
Aug 14, 2020
From: CHAO, MARK PING; MAJETI, RAVINDRA; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; MAUTE, ROY LOUIS
To: FORTY SEVEN, INC.
Reel/Frame 053504/0067 →
Assignment of Assignor's Interest
Aug 18, 2020
From: CHAO, MARK PING; MAUTE, ROY LOUIS; HUANG, JIE; AGORAM, BALAJI
To: FORTY SEVEN, INC.
Reel/Frame 053527/0141 →
Assignment of Assignor's Interest
Sep 1, 2020
From: CHAO, MARK PING; MAJETI, RAVINDRA; TAKIMOTO, CHRIS HIDEMI MIZUFUNE
To: FORTY SEVEN, INC.
Reel/Frame 053659/0415 →
Assignment of Assignor's Interest
Sep 2, 2020
From: CHAO, MARK PING; MAJETI, RAVINDRA; TAKIMOTO, CHRIS HIDEMI MIZUFUNE; MAUTE, ROY LOUIS
To: FORTY SEVEN, INC.
Reel/Frame 053677/0639 →
Assignment of Assignor's Interest
Sep 24, 2020
From: FORTY SEVEN, INC.
To: ARES TRADING S.A.
Reel/Frame 053875/0231 →
Assignment of Assignor's Interest
Nov 10, 2020
From: CAO, YINUO; CHAO, MARK PING; MAJETI, RAVINDRA; MAUTE, ROY LOUIS
To: FORTY SEVEN, INC.
Reel/Frame 054325/0057 →
Assignment of Assignor's Interest
Dec 1, 2020
From: MAJETI, RAVINDRA; WEISMANN, IRVING L.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 054506/0564 →
Assignment of Assignor's Interest
Dec 1, 2020
From: CHAO, MARK P.; LIU, JIE; VOLKMER, JENS-PETER
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; FORTY SEVEN, INC.
Reel/Frame 054506/0596 →
Assignment of Assignor's Interest
Dec 7, 2020
From: AGORAM, BALAJI; CHAO, MARK PING; HUANG, JIE; MAUTE, ROY LOUIS
To: FORTY SEVEN, INC.
Reel/Frame 054565/0476 →